Nature of Business and Basis and Summary of Significant Accounting Policies (Details)	3 Months Ended
	Mar. 31, 2013 item
Nature of Business and Basis of Presentation
Number of prior therapies after which the drug Promalyst can be used to treat relapsed and refractory multiple myeloma as approved by the FDA	2
Period for demonstration of disease progression from completion of the last therapy	60 days